al-01567 has been researched along with galactose in 1 studies
| Studies (al-01567) | Trials (al-01567) | Recent Studies (post-2010) (al-01567) | Studies (galactose) | Trials (galactose) | Recent Studies (post-2010) (galactose) |
|---|---|---|---|---|---|
| 13 | 0 | 2 | 18,988 | 193 | 4,605 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kador, PF; Kinoshita, JH; Sharpless, NE | 1 |
1 review(s) available for al-01567 and galactose
| Article | Year |
|---|---|
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Models, Animal; Fluorenes; Galactose; Humans; Hydantoins; Imidazoles; Imidazolidines; Models, Molecular; Naphthalenes; Phthalazines; Rhodanine; Sorbitol; Structure-Activity Relationship; Substrate Specificity; Sugar Alcohol Dehydrogenases; Thiazolidines; Tissue Distribution | 1985 |